Vaxcyte, Inc. (PCVX)
58.52
-0.88
(-1.48%)
USD |
NASDAQ |
Nov 18, 16:00
58.56
+0.04
(+0.08%)
After-Hours: 20:00
Vaxcyte Enterprise Value : 7.667B for Nov. 18, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 18, 2026 | 7.667B |
| November 17, 2026 | 7.798B |
| November 16, 2026 | 8.128B |
| November 13, 2026 | 8.391B |
| November 12, 2026 | 8.588B |
| November 11, 2026 | 9.175B |
| November 10, 2026 | 8.837B |
| November 09, 2026 | 9.012B |
| November 06, 2026 | 8.468B |
| November 05, 2026 | 8.174B |
| November 04, 2026 | 8.736B |
| November 03, 2026 | 8.008B |
| November 02, 2026 | 7.980B |
| October 30, 2026 | 8.191B |
| October 29, 2026 | 8.277B |
| October 28, 2026 | 8.106B |
| October 27, 2026 | 7.988B |
| October 26, 2026 | 7.883B |
| October 23, 2026 | 7.952B |
| October 22, 2026 | 8.313B |
| October 21, 2026 | 8.370B |
| October 20, 2026 | 8.818B |
| October 19, 2026 | 8.437B |
| October 16, 2026 | 8.428B |
| October 15, 2026 | 8.674B |
| Date | Value |
|---|---|
| October 14, 2026 | 9.015B |
| October 13, 2026 | 8.903B |
| October 12, 2026 | 9.478B |
| October 09, 2026 | 9.587B |
| October 08, 2026 | 8.636B |
| October 07, 2026 | 8.927B |
| October 06, 2026 | 8.888B |
| October 05, 2026 | 9.951B |
| October 02, 2026 | 7.362B |
| October 01, 2026 | 7.298B |
| September 30, 2026 | 7.425B |
| September 29, 2026 | 6.837B |
| September 28, 2026 | 7.065B |
| September 25, 2026 | 6.767B |
| September 24, 2026 | 6.867B |
| September 23, 2026 | 6.808B |
| September 22, 2026 | 7.174B |
| September 21, 2026 | 7.159B |
| September 18, 2026 | 7.045B |
| September 17, 2026 | 7.369B |
| September 16, 2026 | 7.138B |
| September 15, 2026 | 7.201B |
| September 14, 2026 | 7.249B |
| September 11, 2026 | 7.239B |
| September 10, 2026 | 7.156B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Moderna, Inc. | 78.56B |
| Vir Biotechnology, Inc. | 1.181B |
| Anavex Life Sciences Corp. | -51.64M |
| Revolution Medicines, Inc. | 32.12B |
| Foghorn Therapeutics, Inc. | -5.021M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -297.06M |
| Total Expenses (Quarterly) | 297.06M |
| EPS Diluted (Quarterly) | -1.995 |
| Earnings Yield | -13.91% |
| Normalized Earnings Yield | -13.91 |